Quantbot Technologies LP Makes New $1.60 Million Investment in Ingevity Corporation $NGVT

Quantbot Technologies LP acquired a new stake in shares of Ingevity Corporation (NYSE:NGVT) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,400 shares of the company’s stock, valued at approximately $1,598,000. Quantbot Technologies LP owned about 0.06% of Ingevity at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Assetmark Inc. boosted its position in shares of Ingevity by 9.6% during the first quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock worth $113,000 after acquiring an additional 139 shares during the last quarter. Advisory Services Network LLC increased its holdings in Ingevity by 4.4% in the 3rd quarter. Advisory Services Network LLC now owns 6,947 shares of the company’s stock valued at $383,000 after acquiring an additional 293 shares during the last quarter. Amundi increased its holdings in Ingevity by 4.8% in the 3rd quarter. Amundi now owns 6,626 shares of the company’s stock valued at $364,000 after acquiring an additional 302 shares during the last quarter. Isthmus Partners LLC lifted its stake in Ingevity by 0.5% in the 4th quarter. Isthmus Partners LLC now owns 72,245 shares of the company’s stock worth $4,275,000 after purchasing an additional 375 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after purchasing an additional 387 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Wall Street Analyst Weigh In

NGVT has been the subject of a number of research analyst reports. Weiss Ratings upgraded Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Wall Street Zen lowered Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Ingevity presently has an average rating of “Hold” and a consensus price target of $80.00.

Ingevity Trading Down 2.0%

Shares of NGVT opened at $68.88 on Tuesday. The stock has a market capitalization of $2.37 billion, a PE ratio of 46.86 and a beta of 1.16. The company’s fifty day moving average is $73.77 and its 200 day moving average is $71.86. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61. Ingevity Corporation has a fifty-two week low of $45.85 and a fifty-two week high of $79.29.

Ingevity (NYSE:NGVT) last released its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The business had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Sell-side analysts expect that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.

Insider Activity at Ingevity

In other Ingevity news, CEO David H. Li sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the sale, the chief executive officer directly owned 120,636 shares of the company’s stock, valued at $9,147,827.88. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $73.72, for a total value of $199,707.48. Following the sale, the senior vice president owned 15,722 shares in the company, valued at approximately $1,159,025.84. This trade represents a 14.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 18,297 shares of company stock valued at $1,381,452. Insiders own 0.88% of the company’s stock.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.